A Chimeric Streptokinase with Unexpected Fibrinolytic Selectivity

Summary

Chimeric 59D8-SK was designed to confer fibrin-selectivity to streptokinase by fusion of the Fab fragment of anti-fibrin antibody 59D8 to the N-terminus of streptokinase (SK: Ile¹-Lys⁴¹⁴). It was expressed in a mouse hybridoma cell line and purified by affinity chromatography on a 59D8-antigen column. Chimeric 59D8-SK is a disulfide-linked heterodimer composed of an antibody light chain (Mr 27,000) and a N-glycosylated chimeric heavy chain (Mr 90,000). The fibrin targeting by 59D8 increased plasma clot lysis by 2-fold, but connecting 59D8 to SK has provided 59D8-SK several unique properties: (i) 59D8-SK activated human Glu-plasminogen with a significant lag period that coincided with limited proteolysis of 59D8-SK similar to that observed for wild-type SK. In a kinetic study, both gave very similar kinetic parameters for the activation of Glu-plasminogen even though 59D8-SK was N-glycosylated in its SK portion; (ii) 59D8-SK was relatively inactive in human plasma, compared to SK, but it became activated in the presence of clots; (iii) 59D8-SK lysed clots slowly but completely whereas SK lysed clots rapidly but incompletely. Even though the mechanism behind these new properties is not fully understood, they are characteristics of a second-generation plasminogen activator.

• References

• 1 Reddy KNN. Streptokinase - Biochemistry and Clinical Application. Enzyme 1988; 40: 79-89
• 2 ISIS-3 (Third international study of infarct survival) Collaborative Group. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770
• 3 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682
• 4 Marder VJ, Sherry S. Thrombolytic therapy: current status (2). N Engl J Med 1988; 318: 1512-1520
• 5 Onundarson PT, Haraldsson HM, Bergmann L, Francis CW, Marder VJ. Plasminogen depletion during streptokinase treatment or two-chain urokinase incubation correlates with decreased clot lysability ex vivo and in vitro. Thromb Haemost 1993; 70: 998-1004
• 6 Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983; 222: 1129-1132
• 7 Malke H, Roe B, Ferretti JJ. Nucleotide sequence of the streptokinase gene from Streptococcus equisimilis H46A. Gene 1985; 34: 357-362
• 8 Haber E, Quertermous T, Matsueda GR, Runge MS. Innovative approaches to plasminogen activator therapy. Science 1989; 243: 51-56
• 9 Schnee JM, Runge MS, Matsueda GR, Hudson NW, Seidman JG, Haber E, Quertermous T. Construction and expression of a recombinant antibody-targeted plasminogen activator. Proc Natl Acad Sci USA 1987; 84: 6904-6908
• 10 Runge MS, Quertermous T, Zavodny PJ, Love TW, Bode C, Freitag M, Shaw S-Y, Huang P, Chou C-C, Mullins D, Schnee J, Savard CE, Rothenberg ME, Newell JB, Matsueda GR, Haber E. A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. Proc Natl Acad Sci USA 1991; 88: 10337-10341
• 11 Yang W-P, Goldstein J, Procyk R, Matsueda GR, Shaw S-Y. Design and evaluation of a thrombin-activatable plasminogen activator. Biochemistry 1994; 33: 2306-2312
• 12 Maley F, Trimble RB, Tarentino AL, Plummer Jr TH. Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. Anal Biochem 1989; 180: 195-204
• 13 Lijnen HR, Van Hoef B, Vandenbossche L, Collen D. Biochemical properties of natural and recombinant staphylokinase. Fibrinolysis 1992; 6: 214-225
• 14 Procyk R, Kudryk B, Callender S, Blomback B. Accessibility of epitopes on fibrin clots and fibrinogen gels. Blood 1991; 77: 1469-1475
• 15 Estrada MP, Hernandez L, Perez A, Rodriguez P, Serrano R, Rubiera R, Pedraza A, Padron G, Antuch W, de la Fuente J, Herrera L. High level expression of streptokinase in Escherichia coli. Biotechnology 1992; 10: 1138-1142
• 16 Brockway WJ, Castellino FJ. A characterization of native streptokinase and altered streptokinase isolated from a human plasminogen activator complex. Biochemistry 1974; 13: 2063-2070
• 17 Wohl RC, Summaria L, Robbins KC. Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37 degrees C. J Biol Chem 1980; 255: 2005-2013
• 18 Robbins KC. The Plasminogen-Plasmin System. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice Colman RW, Hirsh J, Marder VJ, Salzman EW. eds. 2nd ed JB Lippincott Company; Philadelphia, PA: 1987: 340-357